Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Hisamitsu Pharmaceutical (4530 JP): Guidance Reiterated Amid Seemingly Temporary Hiccup in Q1FY26

Hisamitsu Pharma (4530 JP): New Products Take Mantle as Salonpas, Mohrus Slows, Guidance Reiterated

Hisamitsu Pharmaceutical (4530 JP): Salonpas Holds Fort; New Products Ramp-Up; Stable FY26 Expected

Event-Driven

Hisamitsu Pharmaceutical Co / Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> announced MBO intending to take it private. The offer has been set at ¥6,082 per share which translates to an offer size of roughly ¥400B.</li>
<li>In 9MFY26, the company reported revenue of ¥114.5B up 3% YoY, mainly driven by the overseas prescription drug business while the Salonpas focused OTC pharmaceutical products, revenue remained flat.</li>
<li>Given the fundamentals with new products gaining momentum, Salonpas getting back on track and overseas market growing the offer price of ¥6082 seems a decent exit opportunity at the moment.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) announced MBO intending to take it private. The offer has been set at ¥6,082 per share which translates to an offer size of roughly ¥400B.
In 9MFY26, the company reported revenue of ¥114.5B up 3% YoY, mainly driven by the overseas prescription drug business while the Salonpas focused OTC pharmaceutical products, revenue remained flat.
Given the fundamentals with new products gaining momentum, Salonpas getting back on track and overseas market growing the offer price of ¥6082 seems a decent exit opportunity at the moment.


Hisamitsu Pharma (4530 JP): MBO at ¥6,082 Offers A Decent Exit Opportunity